AbCellera

AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases.[1] The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office.[2] AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days."[3] Its platform for single-cell screening was initially developed at the University of British Columbia.[4]

AbCellera Biologics Inc.
TypePublic Company
IndustryBiotechnology
Founded2012 
HeadquartersVancouver, British Columbia
Websitewww.abcellera.com 

History

AbCellera was founded in 2012 by biomedical researchers Carl Hansen and Véronique Lecault. In November 2016, the company received a US$645K grant from the Bill & Melinda Gates Foundation to develop a test for tuberculosis.[5] In September 2018, a $10M series A round of funding was closed.[6] In May 2020, a $105M series B round of funding was closed.[7][8]

In June 2020, the company announced it had begun the world's first study of a potential antibody treatment against COVID-19, with a Phase 1 trial of LY-CoV555 (Bamlanivimab), in collaboration with Eli Lilly and Company.[9]

Other partnerships include collaborations with GlaxoSmithKline, Novartis, Pfizer, Sanofi and Teva Pharmaceutical Industries.[10]

References
  1. "AbCellera Biologics: Overview". Crunchbase. Retrieved 2020-02-16.
  2. Niiler, Eric (2020-02-14). "Darpa Cranks Up Antibody Research to Stall Coronavirus". Wired. Condé Nast. Retrieved 2020-02-16.
  3. Cumbers, John (2020-02-05). "The Synthetic Biology Companies Racing To Fight Coronavirus". Forbes. Retrieved 2020-02-16.
  4. Shore, Randy (2017-03-03). "B.C.'s biotech leaders are growing up and going global". Vancouver Sun. Postmedia Network. Retrieved 2020-02-16.
  5. "Grant: AbCellera Biologics Inc". Bill & Melinda Gates Foundation. November 2016. Retrieved 2020-02-16.
  6. McGrane, Clare (2018-09-27). "AbCellera raises $10M for machine-learning fueled antibody discovery platform". GeekWire. Retrieved 2020-02-16.
  7. Gormley, Brian (2020-05-27). "AbCellera Banks $105 Million for Antibodies, Including for Covid-19". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-07-21.
  8. Knapp, Alex. "AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases". Forbes. Retrieved 2020-07-21.
  9. "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans". Lilly. 1 June 2020. Retrieved 4 June 2020.
  10. "AbCellera collaborates with Novartis for antibody discovery". PharmaTimes. 2019-02-14. Retrieved 2020-02-16.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.